Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Apr;12(Suppl 1):S18-S19.
doi: 10.21037/jgo-2020-08.

Adjuvant HIPEC for gastric cancer

Affiliations
Editorial

Adjuvant HIPEC for gastric cancer

Paul H Sugarbaker et al. J Gastrointest Oncol. 2021 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jgo-2020-08). The focused issue was sponsored by the Peritoneal Surface Oncology Group International (PSOGI). Drs. PHS and KVDS served as the unpaid Guest Editors of the focused issue. The authors have no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Progression-free and overall survival for gastric cancer. (A) Progression-free survival in 123 gastric cancer patients in HIPEC and control groups (P<0.001). (B) Overall survival in 123 gastric cancer patients in HIPEC and control groups (P=0.2).

Comment on

References

    1. Reutovich MY, Krasko OV, Sukonko OG. Hyperthermic intraperitoneal chemotherapy in prevention of gastric cancer metachronous peritoneal metastases: a systematic review. J Gastrointest Oncol 2021;12:S5-17. - PMC - PubMed
    1. Koga S, Hamazoe R, Maeta M, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988;61:232-7. 10.1002/1097-0142(19880115)61:2<232::AID-CNCR2820610205>3.0.CO;2-U - DOI - PubMed